female sexual dysfunction

BioSante: If at First You Don't Succeed, Spend Millions of Dollars

BioSante: If at First You Don't Succeed, Spend Millions of Dollars

Motley Fool

BioSante Tries Again to Show Female Libido Drug Works

BioSante Tries Again to Show Female Libido Drug Works

Minyanville

Apricus Biosciences Announces Poster Presentation of Femprox Phase III Clinical Data at American Urological Association Annual Meeting

Apricus Biosciences Announces Poster Presentation of Femprox Phase III Clinical Data at American Urological Association Annual Meeting

Pharmalive

BioSante CEO hasn't given up on LibiGel, BioMedReports says

BioSante CEO hasn't given up on LibiGel, BioMedReports says

Yahoo/Fly on the Wall

BioSante Pharmaceuticals Reports Positive LibiGel Safety Data Review for Phase III Program

BioSante Pharmaceuticals Reports Positive LibiGel Safety Data Review for Phase III Program

Pipeline Review

BioSante: LibiGel Lives On, FDA Word On Bio-T-Gel May Come At Any Time

BioSante: LibiGel Lives On, FDA Word On Bio-T-Gel May Come At Any Time

Seeking Alpha

BioSante’s Female Desire Drug Fails to Boost Libido in Late-Stage Studies

BioSante’s Female Desire Drug Fails to Boost Libido in Late-Stage Studies

Bloomberg

[video] The Next Big Thing In Biotech: Biosante

[video] The Next Big Thing In Biotech: Biosante

TheStreet.com

BioSante Rising as Female Libido Drug Moves Foward

BioSante Rising as Female Libido Drug Moves Foward

Minyanville

BioSante: Study Generates Confidence For Future Treatment

BioSante: Study Generates Confidence For Future Treatment

Seeking Alpha